An in vitro assay system using patient‑derived tumor models represents a promising
preclinical cancer model that replicates the disease better than traditional cell culture …

Lung cancer is the most common cancer and the leading cause of cancer-related death
worldwide. However, mechanisms of its progression remained unclear and new treatments …

Establishing appropriate preclinical models is essential for cancer research. Evidence
suggests that cancer is a highly heterogeneous disease. This follows the growing use of …

Cancers remain a major public health problem worldwide, which still require profound
research in both the basic and preclinical fields. Patient-derived xenograft (PDX) models are …

Tumor development and progression require chemical and mechanical cues derived from
cellular and non-cellular components in the tumor microenvironment, including the …

Gastrointestinal (GI) cancers (gastric cancer, oesophageal cancer, liver cancer, colorectal
cancer, etc.) are the most common cancers with the highest morbidity and mortality in the …

The need for pre-clinical models to better predict the individual clinical outcome has driven
the development of improved patient-derived models. Among variety of cancer models …

Anticancer drug discovery and development using conventional cell line and animal models
has traditionally had a low overall success rate. Despite yielding game-changing new …

Patient-derived xenografts (PDXs) describe models involving the implantation of patient-
derived tumor tissue into immunodeficient mice. Compared with conventional preclinical …

Tumor models in vitro are conventional methods for developing anti-cancer drugs,
evaluating drug delivery, or calculating drug efficacy. However, traditional cell line-derived …